129 related articles for article (PubMed ID: 38237426)
21. Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.
Zhu R; Wang Z; Hu Y
Clin Endocrinol (Oxf); 2020 Apr; 92(4):295-302. PubMed ID: 31945198
[TBL] [Abstract][Full Text] [Related]
22. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.
Cascón A; Huarte-Mendicoa CV; Javier Leandro-García L; Letón R; Suela J; Santana A; Costa MB; Comino-Méndez I; Landa I; Sánchez L; Rodríguez-Antona C; Cigudosa JC; Robledo M
Genes Chromosomes Cancer; 2011 Nov; 50(11):922-9. PubMed ID: 21837707
[TBL] [Abstract][Full Text] [Related]
23. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
Parfitt J; Harris M; Wright JM; Kalamchi S
J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
[TBL] [Abstract][Full Text] [Related]
24. Parathyroid carcinoma during pregnancy: a novel pathogenic CDC73 mutation - a case report.
Dematapitiya C; Perera C; Pathmanathan S; Subasinghe V; Anandagoda G; Dissanayaka V; Wijenayake U; Dissanayake P; Gamage K; Wijewickrama P; Sumanatilleke M
BMC Endocr Disord; 2022 Oct; 22(1):259. PubMed ID: 36284286
[TBL] [Abstract][Full Text] [Related]
25. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
27. Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders.
Canaff L; Guarnieri V; Kim Y; Wong BYL; Nolin-Lapalme A; Cole DEC; Minisola S; Eller-Vainicher C; Cetani F; Repaci A; Turchetti D; Corbetta S; Scillitani A; Goltzman D
Eur J Endocrinol; 2022 Feb; 186(3):351-366. PubMed ID: 35038313
[TBL] [Abstract][Full Text] [Related]
28. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum.
Frank-Raue K; Haag C; Schulze E; Keuser R; Raue F; Dralle H; Lorenz K
Eur J Endocrinol; 2011 Sep; 165(3):477-83. PubMed ID: 21652691
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and morphological characteristics of parathyroid carcinoma].
Voronkova IA; Mokrysheva NG; Kazantseva IA; Gurevich LE
Arkh Patol; 2018; 80(4):65-72. PubMed ID: 30059074
[TBL] [Abstract][Full Text] [Related]
30. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
Ababneh E; Nosé V
Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid Cancer in the Pediatric Patient.
Davidson JT; Lam CG; McGee RB; Bahrami A; Diaz-Thomas A
J Pediatr Hematol Oncol; 2016 Jan; 38(1):32-7. PubMed ID: 26650250
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.
Cardoso L; Stevenson M; Thakker RV
Hum Mutat; 2017 Dec; 38(12):1621-1648. PubMed ID: 28881068
[TBL] [Abstract][Full Text] [Related]
33. A novel CDC73 gene mutation in an Italian family with hyperparathyroidism-jaw tumour (HPT-JT) syndrome.
Chiofalo MG; Sparaneo A; Chetta M; Franco R; Baorda F; Cinque L; Granatiero M; D'Agruma L; Pezzullo L; Scillitani A; Guarnieri V
Cell Oncol (Dordr); 2014 Aug; 37(4):281-8. PubMed ID: 25113791
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
Tora R; Welch J; Sun J; Agarwal SK; Bell DA; Merino M; Weinstein LS; Simonds WF; Jha S
J Clin Endocrinol Metab; 2023 Nov; 108(12):3165-3177. PubMed ID: 37339334
[TBL] [Abstract][Full Text] [Related]
35. Establishment of induced pluripotent stem cell lines from an ARVC patient carrying a heterozygous variant in LAMA2 gene.
Wang Y; Fang Y; Wang Y; Xia S; Zhang D; An Q; Li Y; Luo S
Stem Cell Res; 2023 Feb; 66():102999. PubMed ID: 36535090
[TBL] [Abstract][Full Text] [Related]
36. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid cancer.
Sharretts JM; Kebebew E; Simonds WF
Semin Oncol; 2010 Dec; 37(6):580-90. PubMed ID: 21167377
[TBL] [Abstract][Full Text] [Related]
38. Generation of an induced pluripotent stem cell line (MUSIi014-A) from an affected member of a family with autosomal dominant diabetes carrying p.L475P mutation in ZYG11A gene associated with a cell cycle arrest in beta-cell.
Chanprasert C; Promnakhon N; Thongsin N; Suwanpitak S; Plengvidhya N; Yenchitsommanus PT; Jungtrakoon Thamtarana P; Wattanapanitch M
Stem Cell Res; 2022 Apr; 60():102715. PubMed ID: 35193007
[TBL] [Abstract][Full Text] [Related]
39. Parathyroid Carcinoma: Diagnosis and Clinical Implications.
Duan K; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():80-97. PubMed ID: 26177319
[TBL] [Abstract][Full Text] [Related]
40. Generation of an induced pluripotent stem cell line (SDQLCHi044-A) from a patient with autosomal dominant mental retardation type 5 harboring heterozygous mutation in SYNGAP1 gene.
Wang Y; Lv Y; Yang X; Li Y; Li Z; Gao Z; Gai Z; Liu Y
Stem Cell Res; 2022 Oct; 64():102922. PubMed ID: 36183676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
